Perritt Capital Management Inc Invests $31,000 in Biomerica, Inc. (NASDAQ:BMRA)

Perritt Capital Management Inc acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 70,000 shares of the company’s stock, valued at approximately $31,000. Perritt Capital Management Inc owned approximately 0.42% of Biomerica as of its most recent SEC filing.

Separately, Russell Investments Group Ltd. increased its stake in Biomerica by 15.0% in the fourth quarter. Russell Investments Group Ltd. now owns 201,563 shares of the company’s stock valued at $252,000 after purchasing an additional 26,288 shares in the last quarter. 22.28% of the stock is currently owned by hedge funds and other institutional investors.

Biomerica Price Performance

BMRA stock opened at $0.31 on Thursday. The company’s 50-day moving average is $0.37 and its 200-day moving average is $0.61. The stock has a market capitalization of $5.24 million, a PE ratio of -0.84 and a beta of -1.09. Biomerica, Inc. has a 1 year low of $0.24 and a 1 year high of $2.13.

Biomerica Profile

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.